CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for POINT Biopharma Global Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

POINT Biopharma Global Inc
4850 West 78th Street
Phone: (317) 543-9957p:317 543-9957 INDIANAPOLIS, IN  46268  United States Fax: (302) 655-5049f:302 655-5049
This company was Merged or Acquired on 12/27/2023.
This company ceased filing statements with the SEC on 1/8/2024.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
POINT Biopharma Global Inc. is a radiopharmaceutical company. The Company is engaged in building a platform for the clinical development and commercialization of radioligands that fight cancer. The Company is focused on transforming precision medicine by combining a portfolio of radiopharmaceutical assets, a seasoned management team, a pipeline, in-house manufacturing capabilities, and secured supply for rare medical isotopes like actinium-225 (Ac) and lutetium-177 (Lu). Its pipeline consists of late-stage programs in prostate cancer (PNT2002) and neuroendocrine tumors (PNT2003). Its Lu-PNT2002 is a late-stage prostate-specific membrane antigen (PSMA) targeted radioligand therapy. Its Lu-PNT2003 is a late-stage somatostatin-targeted radioligand in development for the treatment of neuroendocrine tumors. Its PNT2004 is a fibroblast activation protein-a (FAP) targeting program being developed for use in multiple tumor types.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202312/31/2022YesYes--Yes

Industries
SIC Code Description
8731 Commercial physical and biological research
6770 Blank checks

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board Allan C.Silber 73
Chief Executive Officer, Director Joe A.Mccann 46 6/1/2021 6/1/2021
Chief Financial Officer BillDemers 65 6/1/2021 6/1/2021
7 additional Officers and Directors records available in full report.

General Information
Number of Employees: 129 (As of 12/31/2022)
Outstanding Shares: 106,569,231 (As of 11/8/2023)
Shareholders: 43
Stock Exchange: NASD
Federal Tax Id: 850800493
Fax Number: (302) 655-5049


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024